Medtronic’s MiniMed 780G Insulin Delivery System Improves Glycemic Control and Simplifies Diabetes Care

Medtronic, a leading medical technology company, has released new clinical and real-world data on its MiniMed 780G insulin delivery system. The latest study focused on analyzing the fixed meal dose and time in range (TIR) outcomes for various users, particularly younger patients who were not meeting their glycemic objectives and those using a simplified meal announcement with preset carbohydrate quantities.

The findings, presented at the 83rd American Diabetes Association (ADA) Scientific Sessions in San Diego, demonstrated the effectiveness of the exclusive meal detection technique and its ability to improve TIR outcomes.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Led by Dr. Goran Petrovski of Sidra Medicine, the initial trial randomly assigned 34 adolescent users to two groups. One group calculated their meal carbohydrates, while the other entered a predefined figure. Prior to participating in the study, the individuals had been using multiple daily injections or pump therapy. The results showed that the fixed carb entry method helped these patients maintain international glycemic objectives for a period of six months without requiring any adjustments to the system.

In Europe and Latin America, a total of 3,543 children under the age of 15, who had a blood glucose level of 100 mg/dL and a two-hour active insulin time, achieved a TIR of 78%. This indicates that the MiniMed 780G system, equipped with its SmartGuard technology, significantly enhanced glycemic control in this particular population, regardless of their baseline control.

Another noteworthy finding from the real-world data was that nearly half of the users of the Medtronic Extended Infusion Set were able to wear it for seven days, aligning with the results of the US pivotal study. This extended wear duration not only reduces the burden on users but also minimizes the need for frequent infusion set adjustments.

Dr. Petrovski, commenting on the study, expressed his excitement about the simplified meal management approach offered by the MiniMed 780G system. He emphasized that this technique helps individuals maintain their glycemic targets even when faced with challenges such as inexact carbohydrate counts. The ability to simplify diabetes care through such innovations is particularly beneficial for individuals who struggle with meal management.

The study demonstrates the positive impact of the exclusive meal detection technique, highlighting its ability to minimize hyperglycemia in both children and adults. With its simplified meal management approach and advanced technologies, the MiniMed 780G system holds promise for individuals seeking enhanced diabetes care and improved quality of life.